Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Senior Vice President Clinical Science and Pharmacology
Puma Biotechnology, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
494 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Sydney West Cancer Trials Centre
Sydney, New South Wales, Australia
- Iron Cancer Care South Brisbane
South Brisbane, Queensland, Australia
- the Queen Elizabeth Hospital
Adelaide, South Australia, Australia
- Ashford Cancer Centre Research
Kurralta Park, South Australia, Australia
- North Adelaide Oncology Calvary Hospital North Adelaide
North Adelaide, South Australia, Australia
- Royal Melbourne Hospital
Melbourne, Victoria, Australia
- the Western Hospital
Melbourne, Victoria, Australia
- Hollywood Private Hospital
Nedlands, Western Australia, Australia
- Olvz Medische Oncologie
Aalst, Belgium
- Az. St. Jan
Bruges, Belgium
- Cliniques Universitaires de Bruxelles
Brussels, Belgium
- Vzw Jesseziekenhuis - Campus Virga Jesse
Hasselt, Belgium
- Jan Yperman Ziekenhuis
Ieper, Belgium
- Az Groeninge Ampus Maria'S Voorzienigheid (mv) Oncologisch Centrum
Kortrijk, Belgium
- Chu de Liège - Domaine Universitaire Du Sart Tilman
Liège, Belgium
- Centre Hospitalier Regional de la Citadelle
Liège, Belgium
- C.H.U. Ambroise Paré
Mons, Belgium
- Az Damiaan - Site Sint-Jozef
Ostend, Belgium
- Az Zusters Van Barmhartigheid
Ronse, Belgium
- Az Nikolaas
Sint-Niklaas, Belgium
- Sint-Elisabethziekenhuis
Turnhout, Belgium
- Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul
Porto Alegre, Rio Grande do Sul, Brazil
- District Dispensary for Oncology Diseases Internal Unit- Plovdiv Eood, Ist
Plovdiv, Bulgaria
- District Dispensary for Oncology Diseases Internal Unit- Plovdiv Eood, Second
Plovdiv, Bulgaria
- District Dispensary for Oncology Diseases Internal Unit- Sofia Eood
Sofia, Bulgaria
- Specialised Hospital of Active Treatment in Oncology
Sofia, Bulgaria
- Interdistrict Dispensary for Oncology Diseases
Varna, Bulgaria
- Cross Cancer Institute
Edmonton, Alberta, Canada
- Jack Ady Cancer Centre
Lethbridge, Alberta, Canada
- Bc Cancer Agency
Vancouver, British Columbia, Canada
- Cancercare Manitoba
Winnipeg, Manitoba, Canada
- London Regional Cancer Program
London, Ontario, Canada
- Stronach Regional Cancer Centre at Southlake
Newmarket, Ontario, Canada
- R.S. Mclaughlin Durham Regional Cancer Centre
Oshawa, Ontario, Canada
- University Health Network, Princess Margaret Hospital
Toronto, Ontario, Canada
- Humber River Regional Hospital - Church Street Site
Weston, Ontario, Canada
- C.H.U.M. - Hopital Notre-Dame, Departement D'Oncologie
Montreal, Quebec, Canada
- Hopital Maisonneuve Rosemont
Montreal, Quebec, Canada
- Hopital Du Sacre-Coeur de Montreal
Montreal, Quebec, Canada
- Csss Alphonse-Desjardins
Québec, Quebec, Canada
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 9 Jul 2009
- Primary completion
- 21 Aug 2014
- Completion
- 4 Oct 2019
- Last update posted
- 11 Jun 2021
- Registered enrollment
- 2,840
- Registry id
- NCT00878709
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.